<DOC>
	<DOCNO>NCT02548468</DOCNO>
	<brief_summary>This phase I trial study side effect best dose donor lymphocyte infusion give together reduce intensity condition regimen partially match donor stem cell transplant treat patient stage IIB-IV mycosis fungoides Sezary syndrome . Giving chemotherapy low-dose total-body irradiation follow high-dose cyclophosphamide donor peripheral blood stem cell transplant help stop growth cell bone marrow , include normal blood-forming cell ( stem cell ) cancer cell . Sometimes transplanted cell donor make immune response body 's normal cell ( call graft-versus-host disease ) . Removing T-cells donor cell give transplant may stop happen . Additionally , give tacrolimus mycophenolate mofetil transplant may also stop happening .</brief_summary>
	<brief_title>Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant Treating Patients With Advanced Cutaneous T Cell Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTVES : I . To evaluate regimen related toxicity , engraftment graft versus host disease ( GVHD ) first 100 day new reduced intensity haploidentical regimen protocol , include fludarabine ( fludarabine phosphate ) , low dose total body irradiation , cyclophosphamide . II . To determine effective donor lymphocyte infusion ( DLI ) dose provide successful engraftment without cause GVHD . SECONDARY OBJECTIVES : I . To assess myeloid lymphoid engraftment rate patient undergoing treatment regimen . II . To determine incidence severity GVHD patient undergo treatment regimen use combination tacrolimus mycophenolate mofetil ( MMF ) GVHD prophylaxis . III . To examine progression free survival overall survival patient cytotoxic T-cell lymphoma ( CTCL ) undergo treatment regimen . IV . To assess pace lymphoid recovery patient population . OUTLINE : This phase I , dose-escalation study DLI . REDUCED INTENSITY CONDITIONING : Patients receive fludarabine phosphate intravenously ( IV ) 30 minute day -11 -8 undergo total body irradiation twice daily ( BID ) day -7 . Patients also receive donor cluster differentiation ( CD ) 3+ enrich T lymphocyte infusion day -6 high-dose cyclophosphamide IV 2 hour day -3 -2 . TRANSPLANT : Patients undergo allogeneic peripheral blood stem cell transplant ( PBSCT ) day 0 . GVHD PROPHYLAXIS : Beginning day -1 , patient receive tacrolimus IV taper ( drug wean ) day 60 mycophenolate mofetil IV BID day -1 28 absence GVHD . After completion treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Stage IIBIV mycosis fungoides sezary syndrome fail least one standard systemic therapy candidate standard therapy . 2 . Patient responsive skin disease include complete remission ( CR ) partial remission ( PR ) ( close CR ; 75 % 99 % clearance skin disease baseline without new tumor ( T3 ) patient T1 , T2 T4 skin disease ) visceral organ lymph node involvement prior transplantation . 3 . Patients must relate donor two allele mismatch HLAA ; B ; C ; DR DQ locus . Patients sibling donor one antigen mismatch due recombination enrol protocol . 4 . Patients must adequate organ function : Left Ventricular Ejection Fraction ( LVEF ) &gt; 50 % Carbon Monoxide Diffusing Capacity ( DLCO ) &gt; 50 % predict correct hemoglobin Adequate liver function define serum bilirubin &lt; 2.0 ( unless hemolysis Gilbert disease ) , Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) &lt; 2.5 X upper limit normal Creatinine clearance &gt; 60 ml/min 5 . Performance status &gt; 80 % ( Karnofsky ) 6 . Hematopoietic Cell Transplantation Specific Comorbidity Index ( HCTCI ) &lt; 5 age &lt; 65 , HCTCI &lt; 4 age &gt; 65 7 . Patients must willing use contraception childbearing potential 8 . Able give inform consent , legally authorize representative give inform consent . 1 . Performance status &lt; 80 % ( Karnofsky ) 2 . HIV positive 3 . Active involvement central nervous system malignancy 4 . Psychiatric disorder would preclude patient sign informed consent 5 . Pregnancy , unwillingness use contraception childbearing potential . 6 . Patients life expectancy &lt; 6 month reason underlie hematologic/oncologic disorder complication . 7 . Patients receive alemtuzumab within 8 week transplant admission , recently receive horse rabbit antithymocyte globulin ( ATG ) ATG level &gt; 2 Î¼gm/ml . 8 . Patients receive cyclophosphamide 9 . Patients evidence another malignancy ( exclusive skin cancer require local treatment ) ; Patients prior malignancy diagnose &gt; 5 year ago without evidence disease eligible . Patients prior malignancy treat &lt; 5 year ago life expectancy &gt; 5 year malignancy eligible . 10 . Uncontrolled active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>